Use of sigma ligands in opioid-induced hyperalgesia

Patent metadata

Field	Value
Publication number	US-9789115-B2
Application number	US-201113814148-A
Country	US
Kind code	B2
Filing date	Aug 2, 2011
Priority date	Aug 3, 2010
Publication date	Oct 17, 2017
Grant date	Oct 17, 2017

Abstract

The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.

First claim

The invention claimed is:

1. A method of treatment and/or prophylaxis of opioid-induced hyperalgesia (OIH) associated with opioid therapy in a patient, the method comprising:
(a) providing a patient who is suffering from OIH associated with opioid therapy, undergoing opioid therapy, or about to undergo opioid therapy, wherein the patient who is undergoing opioid therapy or is about to undergo opioid therapy is or will be receiving a dose of opioid that would be expected to induce OIH in the patient; and
(b) administering to the patient a therapeutically effective amount of a sigma ligand, wherein the sigma ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine:
or a pharmaceutically acceptable salt or solvate thereof,

whereby OIH in the patient is treated, prevented, or ameliorated.

2. The method of claim 1 , wherein the sigma ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy] ethyl} morpholine hydrochloride.

3. A method of treatment and/or prophylaxis of opioid-induced hyperalgesia (OIH) associated with opioid therapy in a patient, the method comprising:
(a) providing a patient who is suffering from OIH associated with opioid therapy, undergoing opioid therapy, or about to undergo opioid therapy, wherein the patient who is undergoing opioid therapy or is about to undergo opioid therapy is or will be receiving a dose of opioid that would be expected to induce OIH in the patient; and
(b) administering to the patient a therapeutically effective amount of a combination of at least one sigma ligand and at least one opioid or opiate compound, wherein said at least one sigma ligand and at least one opioid or compound are administered simultaneously, separately, or sequentially to the patient,
wherein the sigma ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine:
or a pharmaceutically acceptable salt or solvate thereof,

whereby OIH in the patient is treated, prevented, or ameliorated.

4. The method of claim 1 , wherein the opioid therapy is selected from the group consisting of morphine therapy, remifentanil therapy, fentanyl therapy, and sufentanil therapy.

5. The method of claim 3 , wherein the sigma ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine hydrochloride.

6. The method of claim 3 , wherein the opioid therapy is selected from the group consisting of morphine therapy, remifentanil therapy, fentanyl therapy, and sufentanil therapy.

Assignees

• Vela Hernández José Miguel
• Zamanillo-Castanedo Daniel
• Puig Riera De Conias Margarita
• Esteve Labor Dr

Inventors

• Vela Hernández José Miguel
• Zamanillo-Castanedo Daniel
• Puig Riera De Conias Margarita

Classifications

• A61P39/00

  General protective or antinoxious agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title